Skip to content

Study · Animal study (in vivo) · rat · 2018

5 results

Highly effective biosynthesis of N-acetylated human thymosin β4 (Tβ4) in Escherichia coli.

Yu R, Cao S, Liu Y, Si X, Fang T, Sun X, Dai H, Xu J, Fang H, Chen W

Artificial cells, nanomedicine, and biotechnology10 Jul 2018Cited by 9 (Europe PMC)

PMID29989423 (opens in a new tab)DOI10.1080/21691401.2018.1489268 (opens in a new tab)PepBankPUB-29989423
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with moderate to severe dry eye disease, N-acetylated rhTβ4 had an excellent therapeutic effect, as the abstract states without numbers.

    In plain wordsIn rats with dry eye, the thymosin beta‑4 made this way had a good treatment effect, but the abstract gives no numbers.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Direction not reportedDry eye disease
    Study

    ratn: not reported in source

    Moderate to severe dry eye disease
    Outcome group
    Ocular surface · Eye
    Studied dose
    Dose not stated

    Source sentences

    Summary
    excellent therapeutic effect on the rats with moderate to severe dry eye disease.
  2. 02LabIn vitro (cell-free)Activity measurement

    N-acetylated rhTβ4 bound actins from different sources.

    In plain wordsIn lab tests, the thymosin beta‑4 made this way bound actin from different sources.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableActin binding of N-acetylated rhTβ4
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The N-acetylated rhTβ4 also showed the activity of binding with actins from different sources

Studies that did not test the peptide alone3

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Other

    N-acetylated rhTβ4 in PBS buffer was stable at 2-8 °C for 24 months without protein degradation or concentration change.

    In plain wordsIn lab tests, the thymosin beta‑4 made this way stayed stable in a fridge for 24 months.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeStorage stability of N-acetylated rhTβ4
    Study

    n: not reported in source

    Outcome group
    Synthesis and manufacturing · Pharmacology

    Measurements

    stability duration
    24 months
    2-8 °C in PBS

    Source sentences

    Summary
    The N-acetylated rhTβ4 could be stable at 2-8 °C for 24 months in PBS buffer without protein degradation and concentration change.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 04LabNot a test of Thymosin beta-4 (human) aloneOther designOther

    In an E. coli expression method, the N-terminal serine of rhTβ4 was 100% acetylated under optimal conditions.

    In plain wordsIn a lab production method, the end of the thymosin beta‑4 molecule was fully modified as planned.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableN-terminal serine acetylation of rhTβ4
    Study

    n: not reported in source

    Outcome group
    Synthesis and manufacturing · Pharmacology

    Measurements

    N-terminal serine acetylation
    100%
    optimal conditions

    Source sentences

    Summary
    Under the optimal conditions, the N-terminal serine residue was shown to be 100% acetylated and the yield of N-acetylated rhTβ4 can reach 200 mg per litre.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 05LabNot a test of Thymosin beta-4 (human) aloneOther designOther

    In an E. coli expression method, the yield of N-acetylated rhTβ4 reached 200 mg per litre.

    In plain wordsIn a lab production method, the yield of thymosin beta‑4 reached 200 mg per litre.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableYield of N-acetylated rhTβ4
    Study

    n: not reported in source

    Outcome group
    Synthesis and manufacturing · Pharmacology

    Measurements

    yield
    200 mg per litre
    optimal conditions

    Source sentences

    Summary
    Under the optimal conditions, the N-terminal serine residue was shown to be 100% acetylated and the yield of N-acetylated rhTβ4 can reach 200 mg per litre.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.